GOSSAMER BIO, INC. Effective Income Tax Rate Reconciliation, Nondeductible Expense, Research and Development, Percent
GOSSAMER BIO, INC. (GOSS) reported Effective Income Tax Rate Reconciliation, Nondeductible Expense, Research and Development, Percent of 0.00% for the 12-month period ending 2020-12-31, per its 10-K filed 2021-02-26.
Discontinued › Expense Statement › Income Tax
us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopment · last filed 2021-02-26
- GOSSAMER BIO, INC. effective income tax rate reconciliation, nondeductible expense, research and development, percent for fiscal 2020 was 0.00%.
- GOSSAMER BIO, INC. effective income tax rate reconciliation, nondeductible expense, research and development, percent for fiscal 2019 was 0.00%, a 100.00% decline from fiscal 2018.
- GOSSAMER BIO, INC. effective income tax rate reconciliation, nondeductible expense, research and development, percent for fiscal 2018 was 3.92%.
| Period end | Effective Income Tax Rate Reconciliation, Nondeductible Expense, Research and Development, Percent 12 month |
|---|---|
| 2020-12-31 | 0.00% 10-K · filed 2021-02-26 |
| 2019-12-31 | 0.00% 10-K · filed 2021-02-26 |
| 2018-12-31 | 3.92% 10-K · filed 2021-02-26 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Cogent Biosciences, Inc. (COGT) | United States | $5.450B | -17.61 |
| PTC THERAPEUTICS, INC. (PTCT) | United States | $5.199B | -177.07 |
| Dianthus Therapeutics, Inc. /DE/ (DNTH) | United States | $5.082B | -27.79 |
| Erasca, Inc. (ERAS) | United States | $5.073B | -19.96 |
| Oruka Therapeutics, Inc. (ORKA) | United States | $5.663B | -43.76 |
| Travere Therapeutics, Inc. (TVTX) | United States | $5.712B | -123.10 |
| Mirum Pharmaceuticals, Inc. (MIRM) | United States | $5.798B | -8.81 |
| Veradermics, Inc (MANE) | United States | $4.839B | |
| Edgewise Therapeutics, Inc. (EWTX) | United States | $4.470B | -22.23 |
| Amneal Pharmaceuticals, Inc. (AMRX) | $6.326B | 25.62 |